Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PIC/S adopts technical interpretation of revised GMP requirements for sterile products

This article was originally published in SRA

Executive Summary

The committee of the international Pharmaceutical Inspection Convention and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) has adopted a long-awaited technical interpretation of the revised good manufacturing practice requirements for sterile medicinal products, which came into effect earlier this year1,2.

You may also be interested in...



EU Issues Plans For Significant Changes To Manufacturing Standards For Sterile Medicines

Long-awaited plans to change the EU guideline on manufacturing standards for sterile medicinal products are out for consultation. The proposals were drafted in cooperation with the World Health Organization and the international pharmaceutical inspectorate group, PIC/S, to ensure global alignment of standards.

Significant Revisions To Annex 1 Cleanroom Standard Soon To Be Released

MHRA inspector and rapporteur Andrew Hopkins anticipates that the long-awaited revision of Annex 1 on environmental monitoring standards for cleanrooms will soon be released and offers a preview of some of the changes.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS114844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel